Quantcast

Latest Rosuvastatin Stories

2011-04-18 01:00:00

MYSTIC, Conn. and DUBLIN, April 18, 2011 /PRNewswire/ -- Amarin Corporation plc (Nasdaq: AMRN), a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today reported positive, statistically significant top-line results from its ANCHOR trial for the Company's lead product candidate, AMR101. The Phase 3 trial met its primary and secondary efficacy endpoints for both the 4 gram and 2 gram daily doses. The purpose of the ANCHOR trial was to demonstrate that...

2011-04-07 07:00:00

FLORHAM PARK, N.J., April 7, 2011 /PRNewswire/ -- Shionogi Inc., the U.S.-based group company of Shionogi & Co., Ltd., today announced the U.S. commercial availability of CUVPOSA(TM) (glycopyrrolate) oral solution, the first and only FDA-approved treatment to reduce chronic severe drooling in patients aged 3 to 16 with neurologic conditions associated with problem drooling, such as cerebral palsy. "Shionogi is proud to expand its mission of helping to bring high quality care to...

2011-04-01 00:06:17

A new National Cancer Institute (NCI) sponsored study being launched this week at Pittsburgh's Allegheny General Hospital (AGH) will evaluate the cholesterol lowering drug Rosuvastatin (Crestor) for its potential to reduce the risk of colon cancer. Pittsburgh, PA (Vocus/PRWEB) March 31, 2011 A new National Cancer Institute (NCI) sponsored study being launched this week at Allegheny General Hospital (AGH) will evaluate the cholesterol lowering drug Rosuvastatin (Crestor) for its potential to...

2011-03-24 07:58:00

WILMINGTON, Del., March 24, 2011 /PRNewswire-USNewswire/ -- Christiana Care Health System's Helen F. Graham Cancer Center is leading a national clinical trial to determine if Crestor® (Rosuvastatin), a cholesterol-lowering drug, can prevent new colon tumors from forming after colon cancer surgery. (Logo: http://photos.prnewswire.com/prnh/20090407/DC95299LOGO) The study seeks to determine if Crestor can stop the growth of tumor cells by blocking some of the enzymes that...

2011-03-16 00:00:30

New Partnership Kicks Off During National Nutrition Month, Bringing Simple, Low-Cholesterol Recipes Directly to Your Kitchen Wilmington, DE (PRWEB) March 15, 2011 AstraZeneca (NYSE:AZN) today announced the launch of a partnership with Food Universityâ“ž¢ "” a culinary education and entertainment platform "” to educate people about the importance of maintaining a healthy diet as one way to help manage cholesterol. In support of its...

2011-03-14 08:00:00

WILMINGTON, Del., March 14, 2011 /PRNewswire/ -- AstraZeneca (NYSE: AZN) today announced the launch of a partnership with Food University(TM) -- a culinary education and entertainment platform -- to educate people about the importance of maintaining a healthy diet as one way to help manage cholesterol. In support of its cholesterol-lowering medication CRESTOR® (rosuvastatin calcium), the AstraZeneca partnership with Food University aims to empower people to take control...

2011-01-27 04:07:00

NEW YORK, Jan. 27, 2011 /PRNewswire/ -- Get content from AstraZeneca at: http://www.thenewsmarket.com/Releases/StoryDetailPage.aspx?GUID=0be570e4-bf68-4c0b-9777-4d22d679e195# Anglo-Swedish pharmaceutical company AstraZeneca announced that revenue for the full year was unchanged at constant exchange rates (CER) at $33,269 million. Strong revenue growth in markets outside the US (up 7% at CER) broadly offset the loss of more than $1.6 billion of revenue in the US from generic competition...

6388b3719f3ae20b74c8355ad2f4eaff1
2011-01-19 10:35:00

Healthy people may derive no benefit from taking cholesterol-lowering statins, according to a review of previous studies. The report, published in The Cochrane Library concluded that statins reduced death rates in high-risk patients but said there was no evidence to justify their use in people at low risk of developing heart disease. The National Institute for Health and Clinical Excellence recommends statins for people who have a 20 percent or greater chance of developing cardiovascular...

2010-12-22 16:00:00

WILMINGTON, Del., Dec. 22, 2010 /PRNewswire/ -- AstraZeneca (NYSE: AZN) announced today that it has notified Abbott that it will discontinue the development of CERTRIAD(TM) (rosuvastatin calcium and fenofibric acid), which was being investigated for the treatment of mixed dyslipidemia. This means the co-development and license agreement with Abbott will end on January 22, 2011. A Complete Response Letter (CRL) for the CERTRIAD New Drug Application (NDA) was received from the U.S. Food...

2010-12-22 16:00:00

ABBOTT PARK, Ill., Dec. 22, 2010 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT) announced today that Abbott and AstraZeneca will discontinue their joint collaboration for the development of CERTRIAD(TM) (rosuvastatin / fenofibric acid delayed release) Capsules. The companies reached this decision after careful consideration of the Complete Response Letter received from the U.S. Food and Drug Administration, the resulting regulatory delay and the commercial attractiveness of the product in...


Word of the Day
barratry
  • The offense of persistently instigating lawsuits, typically groundless ones.
  • An unlawful breach of duty on the part of a ship's master or crew resulting in injury to the ship's owner.
  • Sale or purchase of positions in church or state.
This word ultimately comes from the Old French word 'barater,' to cheat.
Related